By laksh5382 
Kevin Sayer, CEO of Dexcom.
Scott Millin | cnbc
shares of dexcom fell 9% in extended trading Thursday after the company released third quarter results It beat analysts’ expectations but saw US revenues decline year over year.
Here’s how the company reported compared with Wall Street’s expectations, based on a survey of LSEG analysts:
- earnings per share: 45 cents adjusted vs. 43 cents expected
- Income: $994 million vs. $990 million expected
The company’s revenue rose 2% to $994.2 million from $975 million a year earlier. Dexcom’s U.S. revenues declined 2% from $713.6 million last year. The company reported net income of $134.6 million, or 34 cents a share, up from $120.7 million, or 29 cents a share, in the same period last year.
Dexcom offers a set of devices such as continuous glucose monitors or CGMs for patients suffering from diabetes. It launched its first in August over-the-counter products Called Stelo, which is for adults who don’t take insulin.
The company maintained its full-year fiscal year guidance and expected revenue of $4 billion to $4.05 billion. Last quarter, Dexcom cut its estimate to $4.35 billion from $4.20 billion in the first quarter,
This led to a decline in Dexcom shares of more than 40% after the release of second-quarter results in July due to missed guidance and revenue. Company CEO Kevin Sayer attributed the challenges to a restructuring of the company’s sales team, fewer new customers than expected, and lower revenue per user.
Sawyer said in a call with investors Thursday that these problems improved during the third quarter.
The company also announced that Dexcom Chief Commercial Officer Terry Lawver will retire at the end of the year. Lauver will remain as a consultant until early next year and Sayer will lead the commercial organization as Dexcom searches for a replacement.